Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
Synthekine Announces Clinical Trial Collaboration with Merck to Evaluate STK-012 In Combination with Keytruda® (Pembrolizumab) and Chemotherapy in Ongoing Randomized Phase 2 Trial in First-Line, PD-L1 Negative Nonsquamous Non-Small Cell Lung Cancer
Friday, February 27, 2026Synthekine Inc an engineered cytokine therapeutics company today announced that it has entered into a clinical trial collaboration and supply agreement with Merck known as MSD outside of the United States and Canada
Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients
Thursday, February 26, 2026Novartis a leading global innovative medicines company today announced plans to establish a new squarefoot radioligand therapy RLT manufacturing site in Denton Texas
Siren Biotechnology Receives FDA Fast Track Designation for SRN-101 for the Treatment of Recurrent High-Grade Glioma
Wednesday, February 25, 2026Siren Biotechnology pioneers of Universal AAV ImmunoGene Therapy for cancer today announced that the US Food and Drug Administration FDA has granted Fast Track Designation to SRN the Companys
PlantArcBio and Helix Sementes e Biotecnologia (Agroceres Group Company) Announce Licensing Collaboration to Advance High-Yield, Drought-Resilient Corn in South America
Tuesday, February 24, 2026PlantArcBio an agbiotechnology company pioneering precision biology for better crop performance and Helix Sementes e Biotecnologia a corn and sorghum seed company within Agroceres Group
FDA Approves Genentech’s Venclexta® Plus Acalabrutinib Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia
Friday, February 20, 2026Genentech a member of the Roche Group announced today that the US Food and Drug Administration FDA has approved the combination regimen of Venclexta venetoclax plus acalabrutinib for the treatment of previously
Evinova Announces Strategic Collaborations with Astellas, AstraZeneca and Bristol Myers Squibb Advancing Its AI-Native Platform to Accelerate Global Clinical Development
Thursday, February 19, 2026Evinova today announced strategic collaborations with global life sciences companies Astellas Pharma Inc Astellas AstraZeneca and Bristol Myers Squibb to accelerate their global clinical development using
Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement
Thursday, February 19, 2026Sensei Biotherapeutics Inc today announced that it has acquired Faeth Therapeutics Inc Faeth a clinicalstage biotechnology company developing multinode therapies that target tumor metabolism and signaling
Essential Pharma strengthens rare disease portfolio with acquisition of Ventavis® (iloprost trometamol) for adult primary pulmonary hypertension
Wednesday, February 18, 2026Essential Pharma a global specialty pharmaceutical company today announces the acquisition of Ventavis iloprost trometamol from Bayer AG including rights to the accompanying Breelib nebuliser delivery technology
Roche announces positive phase III results for Gazyva/Gazyvaro in primary membranous nephropathy, marking a significant milestone in this autoimmune disease
Tuesday, February 17, 2026Roche announced today that the phase III MAJESTY study in adults with primary membranous nephropathy met its primary endpoint showing statistically significant and clinically meaningful results with GazyvaGazyvaro
CStone Announces FDA Clearance of IND Application for Its Novel Trispecific Antibody CS2009 (PD-1/VEGF/CTLA-4) to Advance into Phase II Clinical Trial
Tuesday, February 17, 2026CStone Pharmaceuticals an innovationdriven biopharmaceutical company focused on the research and development of therapies for oncology autoimmuneinflammation and other key disease areas today announced that the US FDA has cleared the IND application
